Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved
neuromodulators on facial lines, wrinkles and animation. Participation is available to women
who have never had a cosmetic procedure above the malar region nor a treatment with a
neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3
(Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order
to determine their baseline dimensions. Imaging will be repeated post injection to determine
change over time.
Phase:
N/A
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA